Señales en vivo de SOBI.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 06:59):

Stats
Volumen de hoy	354 251
Volumen promedio	560 308
Capitalización de mercado	97.00B
EPS	SEK0 ( 2024-04-24 )
Próxima fecha de ganancias	( SEK0.560 ) 2024-07-15
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	45.23
ATR14	SEK0.234 (0.08%)

Volumen Correlación

Largo: -0.31 (neutral)

Corto: -0.91 (very strong negative)

Signal:(35.175) Neutral

Swedish Orphan Biovitrum Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Swedish Orphan Biovitrum Correlación - Moneda/Commodity

0.17
( neutral )

0.22
( neutral )

-0.19
( neutral )

-0.31
( neutral )

-0.35
( neutral )

Swedish Orphan Biovitrum Finanzas

Annual	2023
Ingresos:	SEK22.12B
Beneficio Bruto:	SEK14.05B (63.52 %)
EPS:	SEK7.47

FY	2023
Ingresos:	SEK22.12B
Beneficio Bruto:	SEK14.05B (63.52 %)
EPS:	SEK7.47

FY	2022
Ingresos:	SEK18.79B
Beneficio Bruto:	SEK14.01B (74.58 %)
EPS:	SEK8.52

FY	2021
Ingresos:	SEK15.53B
Beneficio Bruto:	SEK12.05B (77.56 %)
EPS:	SEK9.09

Financial Reports:

No articles found.

Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.